Riad Sherif, Oculis CEO
May 22, 2023 07:27 AM EDT
R&D

Oculis says its eye drops passed an ear­ly PhI­II test. Re­searchers have to re­peat it to win ap­proval

Max Gelman

Senior Editor

A Swiss biotech fo­cused on de­vel­op­ing new eye treat­ments tout­ed pos­i­tive da­ta from the first part of a mul­ti-stage Phase III pro­gram Mon­day morn­ing. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times